Biology News
Veterinary Biochemistry Analyzers Market Dynamics, Segments and Supply Demand By 2023 - Pharmaceuticals News


Pharmaceuticals News
Veterinary biochemistry analyzers enable testing to be performed quickly and accurately for immediate diagnosis and health check for animals. They are also used in emergency situation, and routine testing. Increasing incidences of disease outbreak in ...

Biochemistry Analyzers Market detailed strategies, Competitive landscaping and developments for next 5 years - Pharmaceuticals News


Pharmaceuticals News
HTF MI published a new industry research that focuses on Biochemistry Analyzers market and delivers in-depth market analysis and future prospects of Global Biochemistry Analyzers market. The study covers significant data which makes the research ...
The Financial Analyst
Business Services
Investor Opinion

Molecular Biology Enzymes Market 2018 Growth 2018 Key Manufacturers Analysis with Sales, Price, Revenue, Gross ... - Pharmaceuticals News


Pharmaceuticals News
Molecular Biology Enzymes Market report tells about the manufacturing process, raw material and equipment suppliers, various manufacturing associated costs, historical & futuristic cost, revenue, demand and supply data, the actual process. Molecular ...
Facts of Week

Isis Pharmaceuticals Inc.

Englewood - United States

Discovers and develops drugs based upon antisense and RNAi technology. Focused on RNA as a therapeutic target. Includes overview of recent research and drug development approaches.

Related
AFT Pharmaceuticals - A New Force In Pharmaceuticals
New Zealand

AFT Pharmaceuticals is a privately owned company with operations in both Australia and New Zealand. The company was founded in 1997 by Dr Hartley Atkinson. AFT operates as a full service pharmaceutical company and also undertakes drug development activities including clinical trials. AFT has a growing portfolio of patented and niche pharmaceuticals which are in the process of being licensed for sale outside the Australasian market.

Australia

Endangered tree in Queensland, Australia. Includes a description and information on its distribution, habitat, threats and recovery plan.

Prolexys Pharmaceuticals, Inc.
United States

Mapping protein-protein interactions and identify new targets for drug discovery to treat cancer and cardiovascular disease. Explains technology platforms and aetology targeted, with FAQ, company alliances and management in Salt Lake City, Utah.

MultiTarget Pharmaceuticals
United States

Manufacturer of AquaPlasmid, a system for the isolation of pure plasmid DNA. The procedure is simpler than alkaline lysis, but the DNA prep is purer than those purified by anion exchange columns, in Salt Lake City, Utah, USA.

Alnylam Pharmaceuticals
United States

Develops novel therapeutics based RNAi. Provides overview of recent drug development programs. Includes company profile and technology information.

Calando Pharmaceuticals
United States

Company developing non-viral technologies for the therapeutic use of RNAi.

RXi Pharmaceuticals
United States

Discovery-stage biotechnology company pursuing the development of RNAi therapeutics for the treatment of neurodegenerative disease, diabetes and obesity.

Quantum Pharmaceuticals
United States

Provides drug discovery using computational technology to simulates intermolecular interactions.

United States

Develops and researches proprietary immunoregulatory compounds for treatment of autoimmune and cardiovascular disorders, inflammation and cancer. Provides information about products and technologies, as well as corporate and investment data. New Haven, CT.

Beximco Pharmaceuticals Ltd.
Bangladesh

Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is one of the largest exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, European Union, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and curr